Drug Trial Radar · NCT04720976
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Mar 23, 2021
Primary completion
Dec 19, 2023
Study completion Dec 19, 2023
Sponsor
- Lead sponsor
- Allist Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Conditions
- Solid Tumor
- NSCLC
Interventions
JAB-3312Drug
JAB-3312 will be administered orally, variable dose.
BinimetinibDrug
Binimetinib will be administered orally.
PembrolizumabDrug
Pembrolizumab will be administered as an intravenous infusion.
SotorasibDrug
Sotorasib will be administered orally.
OsimertinibDrug
Osimertinib will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicitiesTime frame: 24 months
- Objective response rate (ORR)Time frame: 24 months
- Duration of response (DOR)Time frame: 24 months
- Duration of response (DCR)Time frame: 24 months
- Progression-free survival (PFS)Time frame: 24 months
- Overall survival (OS)Time frame: 24 months
- Number of participants with adverse eventsTime frame: 24 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Los Angeles, California
Research Site
New Haven, Connecticut
Research Site
Jacksonville, Florida
Research Site
Orange City, Florida
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Detroit, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
Oklahoma City, Oklahoma
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.